Specific keynote: Immunological therapy for ovarian cancer

被引：9

作者：

Berek, JS ^{[1
]}

Dorigo, O ^{[1
]}

Schultes, B ^{[1
]}

Nicodemus, C ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, AltaRex Corp, Los Angeles, CA 90024 USA

来源：

GYNECOLOGIC ONCOLOGY | 2003年 / 88卷 / 01期

关键词：

D O I：

10.1006/gyno.2002.6695

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：S105 / S109

页数：5

共 35 条

[1]

ALLAVENA P, 1990, CANCER RES, V50, P7318

[2] CLINICAL COURSE OF OVARIAN-CANCER PATIENTS UNDER REPEATED STIMULATION OF HAMA USING MAB-OC125 AND B43.13 [J].

BAUM, RP ;

NOUJAIM, AA ;

NANCI, A ;

MOEBUS, V ;

HERTEL, A ;

NIESEN, A ;

DONNERSTAG, B ;

SYKES, T ;

BONIFACE, G ;

HOR, G .

HYBRIDOMA, 1993, 12 (05) :583-589

[3]

BEREK JS, 1985, CANCER RES, V45, P4447

[4] Intraperitoneal α-interferon alternating with cisplatin in residual ovarian carcinoma:: A phase II Gynecologic Oncology Group study [J].

Berek, JS ;

Markman, M ;

Blessing, JA ;

Kucera, PR ;

Nelson, BE ;

Anderson, B ;

Hanjani, P .

GYNECOLOGIC ONCOLOGY, 1999, 74 (01) :48-52

[5] INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON [J].

BEREK, JS .

EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :719-721

[6]

BEREK JS, 1991, GYNECOL ONCOL, V40, P237

[7] Intraperitoneal interferon-α in residual ovarian carcinoma:: A Phase II Gynecologic Oncology Group study [J].

Berek, JS ;

Markman, M ;

Stonebraker, B ;

Lentz, SS ;

Adelson, MD ;

DeGeest, K ;

Moore, D .

GYNECOLOGIC ONCOLOGY, 1999, 75 (01) :10-14

[8]

BEREK JS, 2000, PRACTICAL GYNECOLOGI, P457

[9]

BEREK JS, 1990, J CLIN ONCOL, V10, P1610

[10]

BOLLE M, 2000, P AN M AM SOC CLIN, V19, pA476

← 1 2 3 4 →